ClinicalTrials.gg
CompletedNCT03385525Updated Apr 20, 2018

Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

A Phase 1 interventional study of BIIB074 and Valproic Acid in Drug Interaction, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-20.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2017, 9 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the effect of multiple doses of the UGT inhibitor valproic acid on the single-dose pharmacokinetics of BIIB074. The secondary objectives of this study are to evaluate the safety and tolerability of BIIB074 when administered alone and when coadministered with the UGT inhibitor valproic acid and to evaluate the effect of the UGT inhibitor valproic acid on the PK of the M13, M14, and M16 metabolites of BIIB074.

02

Conditions studied

  • Drug Interaction

Keywords

  • Healthy Volunteer
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Must have a between 18 and 32 kg/m\^2, inclusive.
  • Must be male, female, or surgically sterile female
  • Must be in good health as determined by the Investigator, based on medical history and screening evaluations.

Key Exclusion Criteria:

  • History of any cardiac, endocrine, gastrointestinal (GI), hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator
  • Clinically significant abnormal laboratory test values, as determined by the Investigator, at Screening or Day -1
  • History of, or positive test result at Screening for, (HIV)
  • Treatment with any prescription or over-the-counter oral medication (excluding acetaminophen) within 14 days prior to Day -1 and an unwillingness or inability to refrain from this treatment during study participation, unless specifically permitted elsewhere within this protocol.
  • Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrollment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    BIIB074 150 mg and Valproic Acid 500 mg

    Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.

    Drug: BIIB074 · Drug: Valproic Acid

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  2. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf) of BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  3. Area Under the Concentration-Time Curve from Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  4. Time to Reach Maximum Observed Concentration (Tmax) for BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  5. Time of Last Measured Serum Concentration (Tlast) of BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  6. Elimination Half-Life (T 1/2) of BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  7. Apparent Clearance (CL/F) of BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  8. Apparent Volume of Distribution (V/F) of BIIB074

    Time frame: Day 1 through Day 8, Day 16 through Day 23

Secondary outcomes

  1. Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Day 32

  2. Number of Participants with Abnormal Change from Baseline of Electrocardiogram (ECG) up to Day 23

    Time frame: Day 1, 3, 8, 13, 16, 18, 23

  3. Number of Participants with Abnormal Change from Baseline of Clinical Laboratory Parameters up to Day 23

    Time frame: Day 3, 8, 13, 16, 18, 23

  4. Number of Participants with Abnormal Change from Baseline of Vital Signs up to Day 23

    Time frame: Day 1, 3, 8, 13, 16, 18, 23

  5. Cmax of BIIB074 Metabolites M13, M14, and M16

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  6. AUCinf of BIIB074 Metabolites M13, M14, and M16

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  7. AUClast of BIIB074 Metabolites M13, M14, and M16

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  8. Tmax of BIIB074 Metabolites M13, M14, and M16

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  9. Tlast of BIIB074 Metabolites M13, M14, and M16

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  10. T1/2 of BIIB074 Metabolites M13, M14, and M16

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  11. Metabolite-to-Parent Ratio in AUC (MRauc) of BIIB074 Metabolites M13, M14, and M16

    Time frame: Day 1 through Day 8, Day 16 through Day 23

  12. Number of Participants with Abnormal Change from Baseline in Columbia Suicide Severity Rating (C-SSRS) scale

    C-SSRS is a suicidal ideation rating used to evaluate suicidality in children ages 12 and up. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent

    Time frame: Day 8, 23, and once between Day 29-32

07

Study locations

1 site
  • Research Site
    Dallas, Texas 75247, United States
08

References and documents

Publications

  • Zhao Y, Kotecha M, Finnigan H, Serenko M, Naik H. Evaluation of the Effect of Uridine Diphosphate-Glucuronosyltransferases (UGT) Inhibition by Valproic Acid on Vixotrigine Pharmacokinetics in Healthy Volunteers. Clin Drug Investig. 2022 Oct;42(10):829-837. doi: 10.1007/s40261-022-01194-y. Epub 2022 Aug 31. PubMed 36045316 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Oct 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Dec 28, 2017
StartActual
Sep 12, 2017
Primary completionActual
Oct 13, 2017
CompletionActual
Oct 13, 2017
Last update
Apr 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03385525
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Dec 28, 2017
Start date
Sep 12, 2017
Primary completion
Oct 13, 2017
Completion
Oct 13, 2017
Last update
Apr 20, 2018

Study contacts

Medical Director
study director · Biogen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vixotrigine · Valproic Acid

Start the discussion